Potential impact of propofol immediately after motor vehicle accident on later symptoms of posttraumatic stress disorder at 6-month follow up: a retrospective cohort study

Masato Usuki1,2,3,4, Yutaka Matsuoka1,2,3,5*, Daisuke Nishi1,2,3,4, Naohiro Yonemoto3,5, Kenta Matsumura1,3, Yasuhiro Otomo6, Yoshiharu Kim1 and Shigenobu Kanba4

Abstract

Introduction: Critically injured patients are at risk of developing posttraumatic stress disorder (PTSD). Propofol was recently reported to enhance fear memory consolidation retrospectively. Thus, we investigated here whether administration of propofol within 72 h of a motor vehicle accident (MVA) affects the subsequent development of PTSD symptoms.

Methods: We examined data obtained from a prospective cohort study of MVA-related injured patients, admitted to the intensive care unit of a general hospital. We investigated the effect of propofol administration within 72 h of MVA on outcome. Primary outcome was diagnosis of full or partial PTSD as determined by the Clinician-Administered PTSD Scale (CAPS) at 6 months. Secondary outcomes were diagnosis of full or partial PTSD at 1 month and CAPS score indicating PTSD at 1 and 6 months. Multivariate analysis was conducted adjusting for being female, age, injury severity score (ISS), and administration of ketamine or midazolam within 72 h of MVA.

Results: Among 300 patients recruited (mean ISS, 8.0; median Glasgow Coma Scale (GCS) score, 15.0; age, 18 to 69 years), propofol administration showed a higher risk for full or partial PTSD as determined by CAPS at 6 months (odds ratio = 6.13, 95% confidence interval (CI): 1.57 to 23.85, P = 0.009) and at 1 month (odds ratio = 1.31, 95% CI: 0.41 to 4.23, P = 0.647) in the multivariate logistic regression. Multivariate regression analysis showed a trend toward adverse effects of propofol on PTSD symptom development at 6 months after MVA (β = 4.08, 95% CI: -0.49 to 8.64, P = 0.080), but not at 1 month after MVA (β = -0.42, 95% CI: -6.34 to 5.51, P = 0.890).

Conclusions: These findings suggest that using propofol in the acute phase after MVA might be associated with the development of PTSD symptoms 6 months later. However, since the design of this study was retrospective, these findings should be interpreted cautiously and further study is warranted.

Introduction

Critically injured patients are at risk of developing posttraumatic stress disorder (PTSD), particularly those injured in a motor vehicle accident (MVA) [1-10]. MVA survivors with psychiatric morbidity such as PTSD have also been found to have significantly lower quality of life and post-accident work potential than those without psychiatric morbidity [11,12]. Thus, it is important to detect MVA survivors at risk of developing later PTSD and prevent it when feasible.

In general, MVA survivors are administered sedatives for agitation while in the intensive care unit (ICU) or in perioperative management after a traumatic experience. The American College of Critical Care Medicine, clinical practice guidelines recommend use of intravenous propofol, midazolam, or lorazepam for sustaining sedation in the ICU [13]. Some researchers have examined whether sedative drugs affect memory function and the subsequent...
development of PTSD symptoms. Fisher et al. reported that midazolam exposure resulted in antegrade memory loss in humans [14]. McGee et al., working on the assumption that midazolam decreases fear memory, examined the effectiveness of midazolam for later PTSD, but found the prevalence of PTSD did not differ between injured soldiers who received the drug intraoperatively, and those who did not [15].

Recently, Hauer et al. reported that retrospectively propofol enhances consolidation of fear memory in rats [16]. Their experiment, using a well-characterized animal model of aversive training, showed results similar to those for MVA survivors who were administered propofol during acute trauma care and later presented with PTSD. It is speculated that the core mechanism behind the development of PTSD is excessive consolidation of and failure to extinguish fear memory; therefore, modulating consolidation of fear memory as part of early intervention after a traumatic experience would be a potential strategy to prevent PTSD symptoms from developing later [17]. However, the findings of Hauer et al. were obtained in an animal model, and it is still unclear whether administration of propofol for MVA survivors in the clinical setting is related to later PTSD development.

We hypothesized that administration of propofol at an early stage after a traumatic experience might increase the risk for PTSD symptoms later, and investigated here whether such administration within 72 h of MVA is associated with the development of PTSD symptoms 6 months later.

**Materials and methods**

**Participants**

*Overview of the Tachikawa cohort of the Motor Vehicle Accident Study*

This study was performed as a part of the Tachikawa cohort of the MVA (TCOM) Study [10], a prospective cohort study which was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the National Disaster Medical Center (NDMC), Tokyo. NDMC serves a population of approximately 1.7 million and its acute critical care center is responsible for level-I trauma service provision. Participants in the present study were patients consecutively admitted to the ICU of NDMC with MVA-related injury between 30 May 2004 and 8 January 2008. During this period, 344 patients met the eligible criteria and were asked to participate in the study. After receiving a description of the study, 300 patients (87.2%) provided written informed consent. The median number of days between the time of MVA (confirmed from ambulance service records) and baseline assessments was 2.3 days (range 0 to 23).

**Study participants**

The inclusion criteria were as follows: i) MVA-related severe physical injury causing a life-threatening or critical condition; ii) consecutive admittance to the NDMC acute critical care center (ICU); iii) age between 18 and 69 years, and iv) native Japanese speaking ability. The exclusion criteria were as follows: i) diffuse axonal injury, brain contusion, or subdural or subarachnoidal bleeding detected by computed tomography and/or magnetic resonance imaging (with the exception of concussion), because the presence of traumatic brain injury creates considerable difficulties when assessing psychological responses to injury; ii) cognitive impairment, defined as a score < 24 on the Mini-Mental State Examination (MMSE); iii) currently suffering from schizophrenia, bipolar disorder, drug (non-alcohol) dependence or abuse, or epilepsy before the MVA; iv) marked serious symptoms such as suicidal ideation, self-harm behavior, dissociation, or a severe physical condition preventing the patient from tolerating the interview, and v) living or working at a location more than 40 km from the NDMC. Whether patients met the inclusion or exclusion criteria was clinically assessed by a trained research nurse or psychiatrist.

**Assessments**

*Baseline and follow-up assessments*

The following baseline data were gathered: general sociodemographics, past history of psychopathology as determined in a structured interview, detailed information about the MVA, vital signs first recorded on admission to the emergency room, injury severity score (ISS) [18], Glasgow Coma Scale (GCS) score [19], MMSE score [20], pain on admission as measured subjectively, consumption of alcohol and tobacco prior to the MVA as determined in the structured interview, and other clinical information. These assessments were performed by a trained research nurse or psychiatrist.

To assess PTSD symptoms at follow-up, trained psychiatrists conducted the Clinician-Administered PTSD Scale (CAPS) at 1 and 6 months after the MVA injury. CAPS is the gold standard for assessing PTSD and involves a structured interview in which a Likert-type rating of frequency (0 to 4) and a separate rating of intensity (0 to 4) for each symptom is assigned [21]. To constitute a symptom, frequency must be ≥ 1 (once or twice a month) and intensity ≥ 2 (moderate). Full PTSD was diagnosed if patients fulfilled all of the symptom criteria (A-1, stressor; B, re-experiencing; C, avoidance; D, hyperarousal; E, duration; and F, impairment) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM), Fourth Edition, Text Revision [22]. Partial PTSD was diagnosed if they fulfilled two of the three symptom criteria B, C, and D, and the criteria...
A random sample of 30 patients assessed by two raters (YM and DN) was used to assess inter-rater reliability. The calculated intraclass correlation coefficient was 1.0.

Administration of propofol
The clinical practice guidelines of the American College of Critical Care Medicine recommend that propofol is administered for ongoing sedation within the first 3 days [13]; therefore, we retrospectively collected data from the medical records on the total dose of propofol over the initial 72-h period and the route of administration. We used propofol (2,6-disopropyl phenol) purchased from AstraZeneca Japan (Osaka, Japan).

Confounding factors
We investigated eight potential confounding variables, namely, female sex, age, ISS, GCS score, pain on admission, and administration of midazolam, morphine, or ketamine, for the following reasons. A meta-analysis revealed that civilian women were consistently at higher risk than men for PTSD [23]. In an epidemiological study, younger persons showed an increased risk of PTSD compared to elderly persons [24]. ISS was chosen as the objective accident-related variable, and GCS score was chosen as a surrogate marker of traumatic brain injury as more severe traumatic brain injury was found to be associated with a diminished risk of PTSD [25]. ISS and GCS score were determined by an emergency physician on admission. Some studies have indicated that the level of pain is significantly associated with subsequent risk of PTSD [26,27] and therefore we investigated whether or not patients complained of pain on admission.

The clinical practice guidelines of the American College of Critical Care Medicine recommend midazolam for short-term use (within 48 to 72 h) and lorazepam for sedation. We therefore investigated whether or not patients significantly associated with subsequent risk of PTSD [26,27].

Statistical analysis
We performed logistic regression analysis with diagnosis of full or partial PTSD at 6 months after the MVA as the primary outcome. Secondary outcomes were diagnosis of full or partial PTSD at 1 month and a CAPS score indicating PTSD at 1 month and 6 months after the MVA. We performed logistic regression analysis and calculated odds ratios (ORs) and 95% confidence intervals (95% CIs) for full and partial PTSD. Univariate regression analysis and multivariate regression analysis were used to examine the effect of using propofol on the CAPS score, accounting for the five potential covariates described above. Additionally, we calculated regression coefficients ($\beta$) and 95% CIs in the regression analysis as secondary outcomes. All analyses were performed using SPSS statistical software version 17.0J for Windows (SPSS, Tokyo, Japan).

As missing values were present at 1 and 6 months due to dropout and other reasons, we performed multiple imputations with SAS 9.1.3 via procedure MI (SAS System for Windows, version 9.1, SAS Institute, Cary, NC).

Results
The demographics and clinical characteristics of participants who were administered propofol within 72 h of an MVA are shown in Table 1. Sixty-seven (22.3%) were women and the mean age of all participants was 36.5 (SD 15.0) years. The median ISS was 8.0 (range 1 to 48) and the median GCS score was 15.0 (range 3 to 15). Twenty-six (9.7%) participants were administered propofol within 72 h of an MVA, at an average dose of 942.2 mg (median 155 mg, 25th percentile 142.5 mg, 75th percentile 477.3 mg, range 60 to 6650 mg). Of the 300 participants, 155 (51.7%) completed the CAPS at the 1-month follow-up and 106 (35.3%) completed it at the 6-month follow-up (Figure 1). Reasons for dropout were as follows: refused to participate in follow-up ($n = 24$), no response to telephone and mail ($n = 126$), moved to an unknown address ($n = 9$), questionnaire data alone ($n = 33$), or excluded due to serious psychiatric symptoms ($n = 2$). None of the participants had died up to the 6-month follow-up. With the imputed data, the mean CAPS score was 18.2 points at 1 month and 14.0 points at 6 months. Ten participants (3.3%) were deemed to have full PTSD at 1 month and 8 (2.7%) were deemed to have full PTSD at 6 months [34]. Forty-two participants (14.0%) had full or partial PTSD at 1 month, with 21 participants (7%) having the same symptom level at 6 months.

Table 2 shows that the participants who were administered propofol had a higher risk of meeting the criteria for full or partial PTSD at 1 month and 6 months after an MVA: on univariate logistic regression, the OR at 1 month was 2.52 (95% CI 0.99 to 6.42, $P = 0.053$) and at 6 months was 5.18 (95% CI 1.81 to 14.81, $P = 0.002$); on multivariate
logistic regression, the OR at 1 month was 1.31 (95% CI 0.41 to 4.23, \(P = 0.647\)) and at 6 months was 6.13 (95% CI 1.57 to 23.85, \(P = 0.009\)).

Table 3 shows the relationship between CAPS score at 1 month and 6 months after an MVA and administration of propofol. Univariate regression analysis revealed that participants who received propofol had more severe PTSD symptoms at 6 months (\(b = 4.84, \ P = 0.045, 95\% \text{ CI} \ 0.01 \text{ to } 9.58\)), whereas multivariate regression analysis showed a non-significant trend toward adverse effects of propofol on PTSD symptom development (\(b = 4.08, \ P = 0.080, 95\% \text{ CI} -0.49 \text{ to } 8.64\)).

**Discussion**

The findings of the present study suggest that the administration of propofol for MVA victims in the acute trauma stage could have adversely affected the later development of PTSD. In logistic regression analysis, use of propofol showed a higher risk for developing full or partial PTSD at 1 and 6 months after injury. However, the association seen on univariate logistic regression was not apparent on multivariate logistic regression at 1 month after MVA. The reasons for this lack of association on multivariate logistic regression might be explained by the confounding factor of physical condition (assessed by the ISS) and the clinical course. Some previous studies have suggested that injury-related PTSD symptoms tend to develop late [35,36]. For instance, 22% of MVA victims have been shown to meet DSM-III-R criteria for PTSD at 6 months after injury and 30% were diagnosed with PTSD at 12 months [35]. Further, 4.2% of US soldiers were found to have problematic PTSD at 1 month after injury compared with 12.0% at 7 months [36]. In the present study, in relation to secondary outcome, the \(b\)-value of regression analysis was over 4 points at 6 months after MVA. This value was comparable to having one further clinical PTSD symptom. This result suggests that propofol administration has adverse effects on not only categorical PTSD diagnosis but also continuous PTSD symptom level.

Several risk factors for PTSD have been reported in a meta-analysis [23]. However, few studies have examined whether propofol is one of these risk factors, and in this respect our findings offer new insight when considering the risk factors for PTSD. Our results are similar to those of Hauer et al. in that propofol enhanced consolidation of retrograde fear memory in rats [16]. They suggested that enhancement of retrograde memory by propofol depends on an indirect activation of CB1 cannabinoid receptors [16]. Their hypothesis was based on the fact that administration of propofol indirectly increases anandamide (one of the main endocannabinoids) within the...
mouse brain by inhibiting fatty acid amide hydrolase, which degrades endocannabinoids [37]. It is well known that endocannabinoids adversely affect a hippocampal-dependent memory task [38]. However, recent studies have demonstrated that endocannabinoids could facilitate emotionally charged memories [38,39]. Accordingly, the formation of emotional memory is similar to the development of PTSD. Patel et al. showed that other intravenous general anesthetics, including midazolam, ketamine, etomidate, and thiopental, did not affect fatty acid amide hydrolase activity at sedative-relevant concentrations [37]. This also raises the possibility that propofol specifically facilitated formation of retrograde fear memory in our study by excluding the effect of other sedative drugs. In addition, our findings might support the previous observation that propofol use in the ICU was associated with delusional memory and PTSD symptoms after discharge [40].

The present study has several limitations. First, the observational design of this study meant we could not divide patients into two groups in regard to the use of propofol and the sample size of patients who were administered propofol was modest. Second, previous studies have pointed out that the length of ICU stay is a predictor of PTSD, a factor we did not investigate due to insufficient data. Third, we wanted to adjust for three potential covariates, namely GCS, pain on admission, and morphine administration, in the multivariate analysis, but could not do so due to data problems. Further studies of these potential confounders are warranted. Fourth, the response rate was low, especially at 6 months. Weisath had pointed out that the high potential loss to follow-up would reduce the predictor value, thus the response rates need to be high in a longitudinal trauma study [41]. In addition, the risk of either type I or II errors increase as time passes. We should evaluate the present results with these points in mind.

Conclusions
The findings of this study indicate that administration of propofol during the acute trauma stage after an MVA may adversely affect the development of later PTSD. However, a retrospective design tends to overestimate the treatment effects, and therefore the findings should be interpreted with caution. Clearly these results are not definitive, but they do provide supplementary evidence to animal studies and could be helpful for emergency physicians to consider. Studies on PTSD risk factors as a result of drug administration for trauma are still relatively few; in particular, the effects of anesthetic drugs on fear memory remained to be investigated. To clarify the correlation

| Table 2 Multivariate analysis of propofol administration and diagnosis of full or partial posttraumatic stress disorder (PTSD) at 1 and 6 months after a motor vehicle accident |
|-----------------------------------------------|
| PTSD diagnosis | Logistic regression at 1 month | Logistic regression at 6 months |
| Covariates | OR | 95% CI | P-value | OR | 95% CI | P-value |
| Full or partial | | | | | | |
| Propofol | 1.31 | 0.41, 4.23 | 0.647 | 6.13 | 1.57, 23.85 | 0.009 |
| Age | 0.99 | 0.97, 1.01 | 0.397 | 1.04 | 1.00, 1.07 | 0.032 |
| Female | 10.02 | 4.33, 23.17 | < 0.001 | 5.76 | 1.97, 16.78 | 0.001 |
| ISS | 1.10 | 1.05, 1.15 | < 0.001 | 1.04 | 0.98, 1.11 | 0.217 |
| Midazolam | 0.46 | 0.12, 1.69 | 0.240 | 0.40 | 0.06, 2.73 | 0.349 |
| Ketamine | 1.91 | 0.62, 5.94 | 0.262 | 1.15 | 0.20, 6.51 | 0.878 |
| Full | | | | | | |
| Propofol | 0.90 | 0.09, 8.98 | 0.928 | 14.63 | 207, 103.29 | 0.007 |
| Age | 1.04 | 0.99, 1.08 | 0.128 | 1.01 | 0.96, 1.06 | 0.819 |
| Female | 7.53 | 1.65, 34.44 | 0.009 | 5.16 | 0.99, 27.04 | 0.052 |
| ISS | 1.07 | 0.98, 1.17 | 0.112 | 0.94 | 0.82, 1.07 | 0.352 |
| Midazolam | 0.42 | 0.02, 7.61 | 0.555 | 0.51 | 0.02, 12.08 | 0.673 |
| Ketamine | 0.96 | 0.07, 14.00 | 0.974 | 1.19 | 0.06, 23.97 | 0.909 |

The independent variable was use of propofol within 72 h of a motor vehicle accident (MVA); n = 300 participants analyzed by multivariate logistic regression analysis of age, female sex, and administration of ketamine or midazolam within 72 h of an MVA. OR, odds ratio; ISS, injury severity score.

| Table 3 Propofol administration and Clinician-Administered posttraumatic stress disorder (PTSD) Scale score 1 and 6 months after a motor vehicle accident (MVA). |
|-----------------------------------------------|
| | Univariate regression | Multivariate regression |
| | | | |
| | β | 95% CI | P-value | | β | 95% CI | P-value |
| 1 month | | | | | | | |
| 4.10 | -1.67, 9.88 | 0.163 | | -0.42 | -6.34, 5.51 | 0.890 |
| 6 months | | | | | | | |
| 4.84 | 0.10, 9.58 | 0.045 | | 4.08 | -0.49, 8.64 | 0.080 |

The independent variable was use of propofol within 72 h of an MVA; n = 300 participants analyzed by multivariate logistic regression analysis of age, female sex, and administration of ketamine or midazolam within 72 h of an MVA.
between the administration of sedative drugs and development of PTSD, further collaborative research from bench to bedside, and between critical care medicine and psychiatry are needed.

**Key messages**

- Modulating the formation of fear memory after trauma is an important strategy to prevent the subsequent development of PTSD symptoms.
- Administration of propofol within 72 h of trauma could adversely affect the development of PTSD symptoms at 6-month follow-up.
- Propofol administration was shown to have adverse effects not only on categorical PTSD diagnosis, but also on continuous PTSD symptom levels.
- The present results support the findings that propofol enhances consolidation of retrograde fear memory via the endocannabinoid system.

**Abbreviations**

CAPS: Clinician-Administered PTSD Scale; DSM: Diagnostic and Statistical Manual of Mental Disorders; GCS: Glasgow Coma Scale; ICU: intensive care unit; ISS: injury severity score; i.v.: intravenous; MMSE: Mini-Mental State Examination; MVA: motor vehicle accident; NDMMC: National Disaster Medical Center, PTSD: posttraumatic stress disorder.

**Acknowledgements**

We thank Dr T Hifumi for useful advice on the drug assessment; Dr T Takagi for his valuable advice on anesthesiology; Mss Noguchi, Kawase, Sano, Hasagawa, and Takahashi for careful recruitment of and communication with the participants, and Ms. Akutsu, Kamoshida, and Suzuki for data management. The authors thank Ms T Usuki for her general support and warm encouragement.

This study was supported by grants (16190501, 19230701 and 20300701) from the Japanese Ministry of Health, Labor, and Welfare (Research on Psychiatric and Neurological Disease and Mental Health) and CREST, the Japan Science and Technology Agency. The funding body did not play any role in the writing of the manuscript or in the decision to submit the manuscript for publication.

**Author details**

1National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo 187-8553, Japan. 2Department of Psychiatry, National Disaster Medical Center, Tokyo 190-0014, Japan. 3CREST, Japan Science and Technology Agency, Tokyo 102-0075, Japan. 4Department of Neuropsychiatry, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan. 5Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan. 6Department of Acute Critical Care and Disaster Medicine, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.

**Authors’ contributions**

MU designed this secondary analysis, participated in data collection, performed statistical analysis and wrote the manuscript. YM conceived the original protocol and revised the manuscript critically for important intellectual content. SK has made contributions to analysis and interpretation of data and revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

**Competing interests**

There are no competing interests to disclose related to this manuscript. Other financial disclosures are as follows: MU has no financial competing interests; YM has received research support from the Japan Science and Technology Agency, CREST and the Ministry of Health, Labor, and Welfare of Japan, Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP and lecture fees from Suntory Wellness Ltd., Eh Lily Japan KK, and Otsuka Pharmaceutical Co., Ltd. DN has received research support from Takeda Industries, Inc. and the Foundation for Total Health Promotion, and lecture fees from QOL Co., Ltd., DHA & EPA Association and NTT DoCoMo, Inc. NY has received research support from the Japan Society for the Promotion of Science and the Japanese Ministry of Health, Labor and Welfare. RM has received research support from the Japan Society for the Promotion of Science, the 26th Research Grant in Medical and Health Science of Meiji Yasuda Life Foundation of Health and Welfare. YO has research support from the Japanese Ministry of Health, Labor, and Welfare. YK has received research support from the Japanese Ministry of Health, Labor, and Welfare, Japan Science and Technology Agency, CREST, and received a grant from GlaxoSmithKline Japan; he has been a speaker for GlaxoSmithKline, Pfizer, Meiji Seika Pharma, Yoshitomi Pharmaceutical and Meiji Yasuda Insurance Co. SK has received a grant from GlaxoSmithKline, Pfizer and Shionogi Pharmaceutical Co. and received research support from the Ono Pharmaceutical Co.; he has been a speaker for Mochida Pharmaceutical, Astellas, GlaxoSmithKline, Asahi Kasei Pharma and Mitsubishi Tanabe Pharma Co.

**Received:** 12 April 2012 **Revised:** 14 September 2012 **Accepted:** 11 October 2012 **Published:** 28 October 2012

**References**

1. Shalev AY, Freedman S, Pen T, Brandes D, Sahar T, Orr SP, Pitman RK: Prospective study of posttraumatic stress disorder and depression following trauma. Am J Psychiatry 1998, 155:630-637.

2. Koren D, Amor J, Klein E: Acute stress response and posttraumatic stress disorder in traffic accident victims: a one-year prospective, follow-up study. Am J Psychia 1999, 156:367-373.

3. Mayou R, Bryant B, Ehlers A: Prediction of psychological outcomes one year after a motor vehicle accident. Am J Psychiatry 2001, 158:1231-1238.

4. Schnyder U, Moergeli H, Trenz O, Klaghofer R, Bubbelger C: Prediction of psychiatric morbidity in severely injured accident victims at one-year follow-up. Am J Respir Crit Care Med 2001, 164(4):653-656.

5. Bryant RA, Harvey AG, Guthrie RW, Moulds ML: Acute psychophysiological arousal and posttraumatic stress disorder: a two-year prospective study. J Trauma Stress 2003, 16:439-443.

6. O'Donnell ML, Creamer M, Pattison P, Atkin C: Psychiatric morbidity following injury. Am J Psychiatry 2004, 161:507-514.

7. Zatzick DF, Rivara FP, Nathens AB, Jurkovich GJ, Wang J, Fan MY, Rousso J, Sallkever DS, Mackenzie EJ: A nationwide US study of post-traumatic stress after hospitalization for physical injury. Psychol Med 2007, 37:1469-1480.

8. Hepp U, Moergeli H, Buchi S, Bruchhaus-Steinert H, Kraemer B, Sensky T, Schnyder U: Post-traumatic stress disorder in serious accidental injury: 3-year follow-up study. Br J Psychiatry 2008, 192:376-383.

9. Schnyder U, Wittmann L, Friedrich-Perez J, Hepp U, Moergeli H: Posttraumatic stress disorder following accidental injury: rule or exception in Switzerland? Psychotther Psychosom 2008, 77:111-118.

10. Matsuoka Y, Nishi D, Nakajima S, Yonemoto N, Hashimoto K, Noguchi H, Homma M, Oteamo Y, Kim Y: The Tachikawa cohort of motor vehicle accident study investigating psychological distress: design, methods and cohort profiles. Soc Psychiatry Psychiatr Epidemiol 2009, 44:333-340.

11. Matsuoka Y, Nishi D, Nakajima S, Yonemoto N, Noguchi H, Homma M, Oteamo Y, Kim Y: Impact of psychiatric morbidity on quality of life after motor vehicle accident at 1-month follow up. Psychiatry Clin Neurosci 2009, 63:235-237.

12. Matthews LR, Work post-traumatic stress disorder in accident survivors with post-traumatic stress disorder. Behav Res Ther 2005, 43:475-480.

13. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chaffin DB, Masica MF, Bjørke HS, Coplin WM, Crippen DW, Fuchs BD, Kelleher RM, Marik PE, Narasayya SA Jr, Murray MJ, Peruzzi WT, Lumb PD, Kelleher RM, Marik PE, Narasayya SA Jr, Murray MJ, Peruzzi WT, Lumb PD.
Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians: Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002, 30:119-141.

14. Fisher J, Hirschman E, Henthorn T, Arndt J, Passannante A. Midazolam amnesia and short-term-working memory processes. Conscious Cogn 2006, 15:54-63.

15. McGhee LL, Maani CV, Garza TH, DeSocio PA, Gaylord KM, Black IH: The relationship of intravenous midazolam and posttraumatic stress disorder development in burned soldiers. J Trauma 2009, 66(Suppl 4):S186-190.

16. Hauer D, Ratanov P, Morena M, Scaccianoce S, Biegel I, Palmyre M, Cuomo V, Roosenbaul D, Schelling G, Campolongo P: Propofol enhances memory formation via an interaction with the endocannabinoid system. Anesthesiology 2011, 114:1380-1388.

17. Matsuzaka Y: Clearance of fear memory from the hippocampus through neurogenesis by omega-3 fatty acids: a novel preventive strategy for posttraumatic stress disorder? Biopsychos Med 2011, 5:3.

18. Baker SP, O'Neill B: The injury severity score: an update. J Trauma 1976, 16:882-885.

19. Teasdale G, Jennett B: Assessment of coma and impaired consciousness. A practical scale. Lancet 1974, 281-94.

20. Scholenberg M, Reichwald U, Domes G, Badke A, Hautzinger M: Ketamine increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol 2003, 139:1005-1013.

21. Weiss DS: Structured Clinical Interview Techniques for PTSD. In Assessing Psychological Trauma and PTSD. 2nd edition. Edited by: Wilson JP, Keane TM. The Guilford Press, 2004:103-121.

22. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. Washington DC and London: American Psychiatric Association; 2000.

23. Brewin CR, Andrews B, Valentine JD: Meta-analysis of risk factors for posttraumatic stress disorder in trauma-exposed adults. J Consult Clin Psychol 2000, 68:748-766.

24. Wittenhijl PJ, Grooten A, Beesdo K, Schonfeld S, Perkonigg A: Posttraumatic stress disorder: diagnostic and epidemiological perspectives. CNS Spectr 2009, 14(Suppl 1):5-12.

25. Zatzick DF, Rivara FP, Jurkovich GJ, Hoge CW, Wang J, Fan MY, Russo J, Trusz SG, Natsheh A, Mackenzie EJ: Multisite investigation of traumatic brain injuries, posttraumatic stress disorder, and self-reported health and cognitive impairments. Arch Gen Psychiatry 2010, 67:1291-1300.

26. Norman SB, Stein MB,Dimsdale JE, Hoyt DB: Pain in the aftermath of trauma is a risk factor for post-traumatic stress disorder. Psychol Med 2008, 38:533-542.

27. Zatzick DF, Galea S: An epidemiologic approach to the development of early trauma focused intervention. J Trauma Stress 2007, 20:401-412.

28. Gelpin E, Bonne-O, Peni T, Brandes D, Shelev AV: Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 1996, 57:390-394.

29. de Roode A, van Gerven JM, Schoenmaker RC, Engbers FH, Olieman W, Kroon JR, Cohen AF, Bovill JG: A comparison of the effects of propofol and midazolam on memory during two levels of sedation by using target-controlled infusion. Anesth Analg 2000, 91:1036-1061.

30. Bryant RA, Creamer M, O'Donnell M, Silove D, McFarlane AC: A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry 2009, 65:438-440.

31. Holbrook TL, Galarneau MR, Dye JL, Quinn K, Dougherty AL: Morphine use after combat injury in Iraq and post-traumatic stress disorder. N Engl J Med 2010, 362:119-117.

32. Schonenberg M, Reichwald U, Domen G, Badke A, Hautzinger M: Ketamine aggravates symptoms of acute stress disorder in a naturalistic sample of accident victims. J Psychopharmacol 2008, 22:493-497.

33. McGhee LL, Maani CV, Garza TH, Gaylord KM, Black IH: The correlation between ketamine and posttraumatic stress disorder in burned service members. J Trauma 2008, 64(Suppl 2):S195-S198, Discussion S197-S198.

34. Neishi D, Noguchi H, Yonemoto N, Nakajima S, Kim Y, Matsuzaka Y: Psychiatric morbidity in 6 months after motor vehicle accident in Japan. Psychosomatics. 

35. Koren D, Amon I, Klein E: Long term course of chronic posttraumatic stress disorder in traffic accident victims: a three-year prospective follow-up study. Behav Res Ther 2001, 39:1449-1453.

36. Grieger TA, Cozza SJ, Ursano RJ, Hoge C, Martinez PE, Engel CC, Wain HJ: Posttraumatic stress disorder and depression in battle-injured soldiers. Am J Psychiatry 2006, 163:1777-1783, quiz 1860.

37. Patel S, Wohlfert ER, Rademacher DJ, Carner EJ, Perry LJ, Kundu A, Falck JR, Nithipatikom K, Campbell WW, Hillard CJ: The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol 2003, 139:1005-1013.

38. Marisano G, Lafenetre P: Roles of the endocannabinoid system in learning and memory. Curr Top Behav Neurosci 2009, 1:201-230.

39. Hemmings HC Jr, Mackie K: The rivers of Lethe and Mnemosyne converge: propofol and memory consolidation. Anesthesiology 2011, 114:1277-1279.

40. Badia-Castello M, Trujillano-Cabello J, Servea-Goixart L, March-Llames J, Rodriguez-Pozo A: Recall and memory after intensive care unit stay. Development of posttraumatic stress disorder. Med Clin (Barc) 2006, 126:561-566.

41. Wessels L: Importance of high response rates in traumatic stress research. Acta Psychiatr Scand Suppl 1989, 355:131-137.

Cite this article as: Usuki et al: Potential impact of propofol immediately after motor vehicle accident on later symptoms of posttraumatic stress disorder at 6-month follow up: a retrospective cohort study. Critical Care 2012 16:R196.